Literature DB >> 17185999

Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.

A Yassen1, E Olofsen, R Romberg, E Sarton, L Teppema, M Danhof, A Dahan.   

Abstract

The objective of this study was to characterize the pharmacokinetic/pharmacodynamic (PK/PD) relationship of buprenorphine and fentanyl for the respiratory depressant effect in healthy volunteers. Data on the time course of the ventilatory response at a fixed P(ET)CO(2) of 50 mm Hg and P(ET)O(2) of 110 mm Hg following intravenous administration of buprenorphine and fentanyl were obtained from two phase I studies (50 volunteers received buprenorphine: 0.05-0.6 mg/70 kg and 24 volunteers received fentanyl: 0.075-0.5 mg/70 kg). The PK/PD correlations were analyzed using nonlinear mixed effects modeling. A two- and three-compartment pharmacokinetic model characterized the time course of fentanyl and buprenorphine concentration, respectively. Three structurally different PK/PD models were evaluated for their appropriateness to describe the time course of respiratory depression: (1) a biophase distribution model with a fractional sigmoid E(max) pharmacodynamic model, (2) a receptor association/dissociation model with a linear transduction function, and (3) a combined biophase distribution-receptor association/dissociation model with a linear transduction function. The results show that for fentanyl hysteresis is entirely determined by the biophase distribution kinetics, whereas for buprenorphine hysteresis is caused by a combination of biophase distribution kinetics and receptor association/dissociation kinetics. The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively. In addition, for buprenorphine, the value of k(on) was 0.246 ml/ng/min and the value of k(off) was 0.0102 min(-1). The concentration-effect relationship of buprenorphine was characterized by a ceiling effect at higher concentrations (intrinsic activity alpha=0.56, 95% confidence interval (CI): 0.50-0.62), whereas fentanyl displayed full respiratory depressant effect (alpha=0.91, 95% CI: 0.19-1.62).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17185999     DOI: 10.1038/sj.clpt.6100025

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers.

Authors:  Mette L Jensen; David J R Foster; Richard N Upton; Kim Kristensen; Steen H Hansen; Niels-Henrik Jensen; Bettina N Nielsen; Ulrik Skram; Hanne H Villesen; Lona Christrup
Journal:  Eur J Clin Pharmacol       Date:  2007-09-16       Impact factor: 2.953

3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats.

Authors:  Yuancheng Chen; Yanguang Cao; Jia Zhou; Xiaoquan Liu
Journal:  Pharm Res       Date:  2009-05-07       Impact factor: 4.200

Review 4.  Pharmacokinetic-pharmacodynamic modelling in anaesthesia.

Authors:  Pedro L Gambús; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 5.  Bioequivalence criteria for transdermal fentanyl generics: do these need a relook?

Authors:  Carmen Walter; Lisa Felden; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

7.  An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.

Authors:  Jijie Li; Kewei Yan; Lisha Hou; Xudong Du; Ping Zhu; Li Zheng; Cairong Zhu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

8.  Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.

Authors:  Anna H C Vlot; Wilhelmus E A de Witte; Meindert Danhof; Piet H van der Graaf; Gerard J P van Westen; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

9.  Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Eveline van Dorp; Elise Sarton; Luc Teppema; Meindert Danhof; Albert Dahan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.

Authors:  Ashraf Yassen; Erik Olofsen; Jingmin Kan; Albert Dahan; Meindert Danhof
Journal:  Pharm Res       Date:  2007-10-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.